The FDA approved Ranluspec, an interchangeable biosimilar referencing Lucentis, as a treatment for vision-threatening retinal diseases, according to a press release from Lupin.
June 05, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
Natco-Lupin get USFDA’s nod for Eribulin Mesylate injection
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
Will Makary's FDA voucher program survive?
Axsome fends off generic competition to narcolepsy med Sunosi until 2040
Novel Lupus Drugs Continue to Shine in Extended Early Data
The FDA granted orphan drug designation and fast track designation to Lacripep, according to a press release from TearSolutions.…
Find the latest Presbyopia news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you…
CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the…
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
FORT LAUDERDALE, Fla. — An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation…
Outlook Therapeutics resubmitted a biologics license application to the FDA for ONS-5010 for the treatment of neovascular…
